INPLASY202430007

Risk of Secondary Immune Thrombocytopenia following Alemtuzumab Treatment for Multiple Sclerosis: A Systematic Review and Meta-analysis

Keywords: Secondary immune thrombocytopenia, Secondary Autoimmune events,Alemtuzumab, Multiple Sclerosis, adverse events, meta-analysis.

Download PDF - 202430007

Review Status: completed and published